Related Experiment Video
Updated: Apr 3, 2026
10:52
Line Shape Analysis of Dynamic NMR Spectra for Characterizing Coordination Sphere Rearrangements at a Chiral Rhenium Polyhydride Complex
Published on: July 27, 2022
3.5K
Toward hypoxia-selective rhenium and technetium tricarbonyl complexes
Andrea J North, David J Hayne, Christine Schieber
1Ludwig Institute for Cancer Research , Melbourne-Austin Branch, 145 Studley Road, Heidelberg, Victoria 3084, Australia.
Inorganic Chemistry
|September 17, 2015
Summary
New technetium and rhenium tricarbonyl complexes show promise as hypoxia-selective imaging and therapeutic agents. These novel compounds demonstrate selective uptake in hypoxic cells and tumor localization, paving the way for targeted cancer treatments.
Area of Science:
- Radiochemistry
- Inorganic Chemistry
- Medical Imaging
Background:
- Hypoxia is a hallmark of solid tumors, driving treatment resistance and metastasis.
- Developing agents that selectively target hypoxic environments is crucial for effective cancer therapy and imaging.
- Technetium and rhenium complexes offer versatile platforms for developing diagnostic and therapeutic radiopharmaceuticals.
Purpose of the Study:
- To synthesize and characterize novel technetium(I) and rhenium(I) tricarbonyl complexes with functionalized ligands.
- To evaluate the hypoxia-selectivity and cellular uptake of these complexes.
- To assess the potential of these complexes as imaging and therapeutic agents for hypoxic tumors.
Main Methods:
- Synthesis of technetium(I) and rhenium(I) tricarbonyl complexes using pyridylhydrazone, dipyridylamine, and pyridylaminocarboxylate ligands.
- Microwave-assisted synthesis for rhenium complexes to reduce reaction times.
- Confocal fluorescent microscopy to track cellular uptake in HeLa cells.
- In vivo studies using a mouse model with human renal cell carcinoma (RCC) xenografts.
Main Results:
- Rhenium tricarbonyl complexes with nitrobenzyl or nitroimidazole functionalized ligands were successfully prepared.
- Luminescence was observed in rhenium complexes with deprotonated p-nitrophenyl pyridylhydrazone ligands, enabling cellular tracking.
- Selected rhenium complexes exhibited enhanced uptake in hypoxic cells compared to normoxic cells.
- A (99m)Tc tricarbonyl complex demonstrated stability in human serum and localized to an RCC tumor in vivo.
Conclusions:
- The synthesized technetium and rhenium tricarbonyl complexes are potential candidates for hypoxia-selective imaging and therapeutic applications.
- The observed hypoxia-selective uptake and tumor localization highlight their potential in targeted cancer therapy.
- Further investigation is warranted to explore their full therapeutic and diagnostic capabilities.
